Key clinical point: Among pediatric patients with pancreatic neoplasms who underwent pancreatic surgery, exocrine pancreatic insufficiency (EPI) occurred early after surgery but did not affect growth course with prompt treatment. Endocrine failure was less common and developed later, highlighting the need for long-term monitoring in this patient population.

Major finding: EPI occurred in 25% of patients within 6 months after surgery, and endocrine failure developed in 12.5% of patients 8-10 years after surgery. All patients with EPI required pancrelipase supplementation. No significant difference was observed in the body mass index z-score at diagnosis vs. the last follow-up.

Study details: This retrospective study included 16 pediatric patients with pancreatic neoplasms who underwent pancreatic surgery (pancreaticoduodenectomy, 50%).

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Bolasco G et al. World J Clin Cases. 2021;9(25):7340-7349. doi: 10.12998/wjcc.v9.i25.7340.

Key clinical point: Among pediatric patients with pancreatic neoplasms who underwent pancreatic surgery, exocrine pancreatic insufficiency (EPI) occurred early after surgery but did not affect growth course with prompt treatment. Endocrine failure was less common and developed later, highlighting the need for long-term monitoring in this patient population.

Major finding: EPI occurred in 25% of patients within 6 months after surgery, and endocrine failure developed in 12.5% of patients 8-10 years after surgery. All patients with EPI required pancrelipase supplementation. No significant difference was observed in the body mass index z-score at diagnosis vs. the last follow-up.

Study details: This retrospective study included 16 pediatric patients with pancreatic neoplasms who underwent pancreatic surgery (pancreaticoduodenectomy, 50%).

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Bolasco G et al. World J Clin Cases. 2021;9(25):7340-7349. doi: 10.12998/wjcc.v9.i25.7340.

Key clinical point: Among pediatric patients with pancreatic neoplasms who underwent pancreatic surgery, exocrine pancreatic insufficiency (EPI) occurred early after surgery but did not affect growth course with prompt treatment. Endocrine failure was less common and developed later, highlighting the need for long-term monitoring in this patient population.

Major finding: EPI occurred in 25% of patients within 6 months after surgery, and endocrine failure developed in 12.5% of patients 8-10 years after surgery. All patients with EPI required pancrelipase supplementation. No significant difference was observed in the body mass index z-score at diagnosis vs. the last follow-up.

Study details: This retrospective study included 16 pediatric patients with pancreatic neoplasms who underwent pancreatic surgery (pancreaticoduodenectomy, 50%).

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Bolasco G et al. World J Clin Cases. 2021;9(25):7340-7349. doi: 10.12998/wjcc.v9.i25.7340.

Key clinical point: Among patients with pancreatic cancer undergoing pancreatectomy, pancreatic fistula (PF) did not affect postoperative pancreatic exocrine function. However, preserved or accelerated exocrine function post-pancreatectomy may cause PF.

Major finding: The levels of ¹³C-trioctanoin absorption (%dose/hour) post- vs. preoperation decreased significantly in the non-PF group (28.5 vs. 36.5; P < .0001) but did not change in the PF group (36.9 vs. 34.5; P = .129). Higher postoperative ¹³C-trioctanoin absorption was independently associated with PF (adjusted odds ratio 1.156; P = .001). Patients with ¹³C-trioctanoin absorption (%dose/hour) of ≥30 vs. <30 had higher postoperative maximum drain amylase levels (2,502 U/L vs. 398 U/L; P = .001).

Study details: This retrospective study included 96 patients with (n = 17) or without (n = 79) PF who underwent ¹³C-trioctanoin breath tests before and approximately 1 month after pancreatectomy.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Higashiguchi T et al. Surg Today. 2021 Sep 16. doi: 10.1007/s00595-021-02371-w.

Key clinical point: Among patients with pancreatic cancer undergoing pancreatectomy, pancreatic fistula (PF) did not affect postoperative pancreatic exocrine function. However, preserved or accelerated exocrine function post-pancreatectomy may cause PF.

Major finding: The levels of ¹³C-trioctanoin absorption (%dose/hour) post- vs. preoperation decreased significantly in the non-PF group (28.5 vs. 36.5; P < .0001) but did not change in the PF group (36.9 vs. 34.5; P = .129). Higher postoperative ¹³C-trioctanoin absorption was independently associated with PF (adjusted odds ratio 1.156; P = .001). Patients with ¹³C-trioctanoin absorption (%dose/hour) of ≥30 vs. <30 had higher postoperative maximum drain amylase levels (2,502 U/L vs. 398 U/L; P = .001).

Study details: This retrospective study included 96 patients with (n = 17) or without (n = 79) PF who underwent ¹³C-trioctanoin breath tests before and approximately 1 month after pancreatectomy.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Higashiguchi T et al. Surg Today. 2021 Sep 16. doi: 10.1007/s00595-021-02371-w.

Key clinical point: Among patients with pancreatic cancer undergoing pancreatectomy, pancreatic fistula (PF) did not affect postoperative pancreatic exocrine function. However, preserved or accelerated exocrine function post-pancreatectomy may cause PF.

Major finding: The levels of ¹³C-trioctanoin absorption (%dose/hour) post- vs. preoperation decreased significantly in the non-PF group (28.5 vs. 36.5; P < .0001) but did not change in the PF group (36.9 vs. 34.5; P = .129). Higher postoperative ¹³C-trioctanoin absorption was independently associated with PF (adjusted odds ratio 1.156; P = .001). Patients with ¹³C-trioctanoin absorption (%dose/hour) of ≥30 vs. <30 had higher postoperative maximum drain amylase levels (2,502 U/L vs. 398 U/L; P = .001).

Study details: This retrospective study included 96 patients with (n = 17) or without (n = 79) PF who underwent ¹³C-trioctanoin breath tests before and approximately 1 month after pancreatectomy.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Higashiguchi T et al. Surg Today. 2021 Sep 16. doi: 10.1007/s00595-021-02371-w.

Key clinical point: Treatment with nonsteroidal anti-inflammatory drugs (NSAID) worsened exocrine pancreatic insufficiency (EPI) in patients with primary osteoarthritis in gastrointestinal comorbidity with EPI. Moreover, the trophologic status of patients also deteriorated, indicating reduced nutrient uptake because of aggravation of EPI.

Major finding: Fecal a-elastase levels decreased, and the CO program score increased significantly after vs. before NSAID treatment, particularly in patients with chronic pancreatitis (all P < .05). Moreover, the levels of trophologic parameters (magnesium, calcium, iron, zinc, selenium, albumin, and vitamins A, E, and K) decreased significantly after NSAID treatment (all P < .05).

Study details: This study included 87 adult patients with primary osteoarthritis along with EPI (chronic pancreatitis, n = 30; chronic nonstone cholecystitis, functional diseases of the gallbladder, and biliary system, n = 28; chronic gastroduodenitis, n = 29) and 30 healthy controls.

Disclosures: This study was funded by the authors’ resources. The authors declared no conflict of interests.

Source: Halabitska IM et al. Fam Med Prim Care Rev. 2021;23(4), Oct 5. doi: 10.5114/fmpcr.2021.108207.

Key clinical point: Treatment with nonsteroidal anti-inflammatory drugs (NSAID) worsened exocrine pancreatic insufficiency (EPI) in patients with primary osteoarthritis in gastrointestinal comorbidity with EPI. Moreover, the trophologic status of patients also deteriorated, indicating reduced nutrient uptake because of aggravation of EPI.

Major finding: Fecal a-elastase levels decreased, and the CO program score increased significantly after vs. before NSAID treatment, particularly in patients with chronic pancreatitis (all P < .05). Moreover, the levels of trophologic parameters (magnesium, calcium, iron, zinc, selenium, albumin, and vitamins A, E, and K) decreased significantly after NSAID treatment (all P < .05).

Study details: This study included 87 adult patients with primary osteoarthritis along with EPI (chronic pancreatitis, n = 30; chronic nonstone cholecystitis, functional diseases of the gallbladder, and biliary system, n = 28; chronic gastroduodenitis, n = 29) and 30 healthy controls.

Disclosures: This study was funded by the authors’ resources. The authors declared no conflict of interests.

Source: Halabitska IM et al. Fam Med Prim Care Rev. 2021;23(4), Oct 5. doi: 10.5114/fmpcr.2021.108207.

Key clinical point: Treatment with nonsteroidal anti-inflammatory drugs (NSAID) worsened exocrine pancreatic insufficiency (EPI) in patients with primary osteoarthritis in gastrointestinal comorbidity with EPI. Moreover, the trophologic status of patients also deteriorated, indicating reduced nutrient uptake because of aggravation of EPI.

Major finding: Fecal a-elastase levels decreased, and the CO program score increased significantly after vs. before NSAID treatment, particularly in patients with chronic pancreatitis (all P < .05). Moreover, the levels of trophologic parameters (magnesium, calcium, iron, zinc, selenium, albumin, and vitamins A, E, and K) decreased significantly after NSAID treatment (all P < .05).

Study details: This study included 87 adult patients with primary osteoarthritis along with EPI (chronic pancreatitis, n = 30; chronic nonstone cholecystitis, functional diseases of the gallbladder, and biliary system, n = 28; chronic gastroduodenitis, n = 29) and 30 healthy controls.

Disclosures: This study was funded by the authors’ resources. The authors declared no conflict of interests.

Source: Halabitska IM et al. Fam Med Prim Care Rev. 2021;23(4), Oct 5. doi: 10.5114/fmpcr.2021.108207.

Key clinical point: Timing of pancreatic enzyme replacement therapy (PERT) did not influence abdominal pain among children and adolescents with cystic fibrosis (CF) and pancreatic insufficiency (PI).

Major finding: No significant change was observed in the occurrence, intensity, and duration of abdominal pain with the change of PERT timing from before to after meals and vice versa (all P > .05).

Study details: This randomized, cross-over trial included 30 Danish patients (age 0-17 years) with CF and PI. Patients were randomly assigned to take their usual PERT dose before meals for 4 weeks, followed by after meals for 4 weeks, and vice versa.

Disclosures: This study was funded by grants from the Danish Ronald McDonald Children’s Fund and the Danish Cystic Fibrosis Foundation to M Skov, AMT Raun, and G Brekke. The authors declared no conflict of interests.

Source: Raun AMT et al. Acta Paediatr. 2021 Oct 8. doi: 10.1111/apa.16143.

Key clinical point: Timing of pancreatic enzyme replacement therapy (PERT) did not influence abdominal pain among children and adolescents with cystic fibrosis (CF) and pancreatic insufficiency (PI).

Major finding: No significant change was observed in the occurrence, intensity, and duration of abdominal pain with the change of PERT timing from before to after meals and vice versa (all P > .05).

Study details: This randomized, cross-over trial included 30 Danish patients (age 0-17 years) with CF and PI. Patients were randomly assigned to take their usual PERT dose before meals for 4 weeks, followed by after meals for 4 weeks, and vice versa.

Disclosures: This study was funded by grants from the Danish Ronald McDonald Children’s Fund and the Danish Cystic Fibrosis Foundation to M Skov, AMT Raun, and G Brekke. The authors declared no conflict of interests.

Source: Raun AMT et al. Acta Paediatr. 2021 Oct 8. doi: 10.1111/apa.16143.

Key clinical point: Timing of pancreatic enzyme replacement therapy (PERT) did not influence abdominal pain among children and adolescents with cystic fibrosis (CF) and pancreatic insufficiency (PI).

Major finding: No significant change was observed in the occurrence, intensity, and duration of abdominal pain with the change of PERT timing from before to after meals and vice versa (all P > .05).

Study details: This randomized, cross-over trial included 30 Danish patients (age 0-17 years) with CF and PI. Patients were randomly assigned to take their usual PERT dose before meals for 4 weeks, followed by after meals for 4 weeks, and vice versa.

Disclosures: This study was funded by grants from the Danish Ronald McDonald Children’s Fund and the Danish Cystic Fibrosis Foundation to M Skov, AMT Raun, and G Brekke. The authors declared no conflict of interests.

Source: Raun AMT et al. Acta Paediatr. 2021 Oct 8. doi: 10.1111/apa.16143.

Key clinical point: Exocrine pancreatic insufficiency (EPI) developed early during carbon ion radiotherapy among patients with pancreatic cancer, suggesting pancreatic sensitivity to carbon-ion beams.

Major finding: Overall, 57.6% of patients developed EPI, defined as both amylase and lipase deficiencies, within 13.6 months during and after carbon-ion radiotherapy. Pancreatic volume that received < 5 Gy at the cutoff value of 4.57 cm³ was the most effective prognostic factor for EPI development (area under the receiver operating characteristic curve 0.74; P = .02).

Study details: Findings are from a retrospective analysis of 33 patients with pancreatic cancer and normal serum pancreatic amylase and lipase levels who underwent carbon-ion radiotherapy.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Shiba S et al. Clin Tranl Radiat Oncol. 2021;31:80-85. doi: 10.1016/j.ctro.2021.09.007.

Key clinical point: Exocrine pancreatic insufficiency (EPI) developed early during carbon ion radiotherapy among patients with pancreatic cancer, suggesting pancreatic sensitivity to carbon-ion beams.

Major finding: Overall, 57.6% of patients developed EPI, defined as both amylase and lipase deficiencies, within 13.6 months during and after carbon-ion radiotherapy. Pancreatic volume that received < 5 Gy at the cutoff value of 4.57 cm³ was the most effective prognostic factor for EPI development (area under the receiver operating characteristic curve 0.74; P = .02).

Study details: Findings are from a retrospective analysis of 33 patients with pancreatic cancer and normal serum pancreatic amylase and lipase levels who underwent carbon-ion radiotherapy.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Shiba S et al. Clin Tranl Radiat Oncol. 2021;31:80-85. doi: 10.1016/j.ctro.2021.09.007.

Key clinical point: Exocrine pancreatic insufficiency (EPI) developed early during carbon ion radiotherapy among patients with pancreatic cancer, suggesting pancreatic sensitivity to carbon-ion beams.

Major finding: Overall, 57.6% of patients developed EPI, defined as both amylase and lipase deficiencies, within 13.6 months during and after carbon-ion radiotherapy. Pancreatic volume that received < 5 Gy at the cutoff value of 4.57 cm³ was the most effective prognostic factor for EPI development (area under the receiver operating characteristic curve 0.74; P = .02).

Study details: Findings are from a retrospective analysis of 33 patients with pancreatic cancer and normal serum pancreatic amylase and lipase levels who underwent carbon-ion radiotherapy.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Shiba S et al. Clin Tranl Radiat Oncol. 2021;31:80-85. doi: 10.1016/j.ctro.2021.09.007.

Key clinical point: The incidence of chronic myeloid leukemia (CML) has increased globally, but the declining death rate indicates improved treatment options. However, patient management, particularly among elderly patients, needs more attention.

Major finding: The incident cases of CML increased globally by 54.1% from 1990 to 2019. The overall age-standardized death rate declined by 2.55% per year, and disease-adjusted life years (DALY) decreased by 2.69% per year. However, patients aged 70-84 years accounted for higher CML incidence and death cases. Smoking was the biggest risk factor for CML-related DALY (12.2%).

Study details: This study used annual data on the CML burden in 204 countries and regions from 1990 to 2019.

Disclosures: This study was supported by the National Natural Science Foundation of China, Taishan Scholars Program, and Clinical Research Project of Shandong University. The authors declared no conflict of interests.

Source: Hu Y et al. JCO Glob Oncol. 2021 (Sep 30);7:1429-1441. doi: 10.1200/GO.21.00194.

Key clinical point: The incidence of chronic myeloid leukemia (CML) has increased globally, but the declining death rate indicates improved treatment options. However, patient management, particularly among elderly patients, needs more attention.

Major finding: The incident cases of CML increased globally by 54.1% from 1990 to 2019. The overall age-standardized death rate declined by 2.55% per year, and disease-adjusted life years (DALY) decreased by 2.69% per year. However, patients aged 70-84 years accounted for higher CML incidence and death cases. Smoking was the biggest risk factor for CML-related DALY (12.2%).

Study details: This study used annual data on the CML burden in 204 countries and regions from 1990 to 2019.

Disclosures: This study was supported by the National Natural Science Foundation of China, Taishan Scholars Program, and Clinical Research Project of Shandong University. The authors declared no conflict of interests.

Source: Hu Y et al. JCO Glob Oncol. 2021 (Sep 30);7:1429-1441. doi: 10.1200/GO.21.00194.

Key clinical point: The incidence of chronic myeloid leukemia (CML) has increased globally, but the declining death rate indicates improved treatment options. However, patient management, particularly among elderly patients, needs more attention.

Major finding: The incident cases of CML increased globally by 54.1% from 1990 to 2019. The overall age-standardized death rate declined by 2.55% per year, and disease-adjusted life years (DALY) decreased by 2.69% per year. However, patients aged 70-84 years accounted for higher CML incidence and death cases. Smoking was the biggest risk factor for CML-related DALY (12.2%).

Study details: This study used annual data on the CML burden in 204 countries and regions from 1990 to 2019.

Disclosures: This study was supported by the National Natural Science Foundation of China, Taishan Scholars Program, and Clinical Research Project of Shandong University. The authors declared no conflict of interests.

Source: Hu Y et al. JCO Glob Oncol. 2021 (Sep 30);7:1429-1441. doi: 10.1200/GO.21.00194.

Key clinical point: Frontline treatment with dasatinib was effective, with an acceptable safety profile in older patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, 93.3%, 77.7%, and 53.3% of patients achieved a complete cytogenic response, major molecular response, and deep molecular response, respectively. At 36 months, cumulative event-free survival and overall survival were 64.7% and 82.3%, respectively. Grade 3 and 4 adverse events were observed in 13.3% and 26.6% of patients, respectively. Treatment discontinuation and dasatinib dose reduction was reported in 20.0% and 53.3% of patients, respectively.

Study details: This retrospective study included 45 older (age ≥75 years) patients with newly diagnosed CML-CP treated with frontline dasatinib followed up for a median duration of 42.6 months.

Disclosures: No source of funding was identified. Some investigators, including the lead author, reported receiving honoraria from various pharmaceutical companies.

Source: Stagno F et al. Acta Oncol. 2021;69(11):1527-1533. doi: 10.1080/0284186X.2021.1971292.

Key clinical point: Frontline treatment with dasatinib was effective, with an acceptable safety profile in older patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, 93.3%, 77.7%, and 53.3% of patients achieved a complete cytogenic response, major molecular response, and deep molecular response, respectively. At 36 months, cumulative event-free survival and overall survival were 64.7% and 82.3%, respectively. Grade 3 and 4 adverse events were observed in 13.3% and 26.6% of patients, respectively. Treatment discontinuation and dasatinib dose reduction was reported in 20.0% and 53.3% of patients, respectively.

Study details: This retrospective study included 45 older (age ≥75 years) patients with newly diagnosed CML-CP treated with frontline dasatinib followed up for a median duration of 42.6 months.

Disclosures: No source of funding was identified. Some investigators, including the lead author, reported receiving honoraria from various pharmaceutical companies.

Source: Stagno F et al. Acta Oncol. 2021;69(11):1527-1533. doi: 10.1080/0284186X.2021.1971292.

Key clinical point: Frontline treatment with dasatinib was effective, with an acceptable safety profile in older patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, 93.3%, 77.7%, and 53.3% of patients achieved a complete cytogenic response, major molecular response, and deep molecular response, respectively. At 36 months, cumulative event-free survival and overall survival were 64.7% and 82.3%, respectively. Grade 3 and 4 adverse events were observed in 13.3% and 26.6% of patients, respectively. Treatment discontinuation and dasatinib dose reduction was reported in 20.0% and 53.3% of patients, respectively.

Study details: This retrospective study included 45 older (age ≥75 years) patients with newly diagnosed CML-CP treated with frontline dasatinib followed up for a median duration of 42.6 months.

Disclosures: No source of funding was identified. Some investigators, including the lead author, reported receiving honoraria from various pharmaceutical companies.

Source: Stagno F et al. Acta Oncol. 2021;69(11):1527-1533. doi: 10.1080/0284186X.2021.1971292.

Key clinical point: Treatment with the second-generation (2G) tyrosine kinase inhibitors (TKI) before allogeneic hematopoietic cell transplantation (allo-HCT) is feasible without any detrimental posttransplant outcomes or additional transplant-related toxicities in patients with chronic myeloid leukemia (CML).

Major finding: During a median follow-up of 37 months posttransplantation, 92% of patients had successful grafts, whereas 3% and 5% of patients experienced primary and secondary graft failure, respectively. At 5 years, nonrelapse mortality, chronic graft versus host disease, and overall survival were 24% (95% CI 19%-29%), 60% (95% CI 54%-66%), and 56% (95% CI 50%-62%), respectively.

Study details: This prospective study included 383 adult patients with CML previously treated with dasatinib (40%), nilotinib (17%), or sequential dasatinib and nilotinib with or without bosutinib or ponatinib (43%) who first underwent allo-HCT.

Disclosures: This study was supported by Novartis. Some investigators reported travel grants, honoraria, speaker fees, advisory board membership, or clinical trial independent data monitoring committee membership with various pharmaceutical companies, including Novartis.

Source: Masouridi-Levrat S et al. Bone Marrow Transplant. 2021 Oct 1. doi: 10.1038/s41409-021-01472-x.

Key clinical point: Treatment with the second-generation (2G) tyrosine kinase inhibitors (TKI) before allogeneic hematopoietic cell transplantation (allo-HCT) is feasible without any detrimental posttransplant outcomes or additional transplant-related toxicities in patients with chronic myeloid leukemia (CML).

Major finding: During a median follow-up of 37 months posttransplantation, 92% of patients had successful grafts, whereas 3% and 5% of patients experienced primary and secondary graft failure, respectively. At 5 years, nonrelapse mortality, chronic graft versus host disease, and overall survival were 24% (95% CI 19%-29%), 60% (95% CI 54%-66%), and 56% (95% CI 50%-62%), respectively.

Study details: This prospective study included 383 adult patients with CML previously treated with dasatinib (40%), nilotinib (17%), or sequential dasatinib and nilotinib with or without bosutinib or ponatinib (43%) who first underwent allo-HCT.

Disclosures: This study was supported by Novartis. Some investigators reported travel grants, honoraria, speaker fees, advisory board membership, or clinical trial independent data monitoring committee membership with various pharmaceutical companies, including Novartis.

Source: Masouridi-Levrat S et al. Bone Marrow Transplant. 2021 Oct 1. doi: 10.1038/s41409-021-01472-x.

Key clinical point: Treatment with the second-generation (2G) tyrosine kinase inhibitors (TKI) before allogeneic hematopoietic cell transplantation (allo-HCT) is feasible without any detrimental posttransplant outcomes or additional transplant-related toxicities in patients with chronic myeloid leukemia (CML).

Major finding: During a median follow-up of 37 months posttransplantation, 92% of patients had successful grafts, whereas 3% and 5% of patients experienced primary and secondary graft failure, respectively. At 5 years, nonrelapse mortality, chronic graft versus host disease, and overall survival were 24% (95% CI 19%-29%), 60% (95% CI 54%-66%), and 56% (95% CI 50%-62%), respectively.

Study details: This prospective study included 383 adult patients with CML previously treated with dasatinib (40%), nilotinib (17%), or sequential dasatinib and nilotinib with or without bosutinib or ponatinib (43%) who first underwent allo-HCT.

Disclosures: This study was supported by Novartis. Some investigators reported travel grants, honoraria, speaker fees, advisory board membership, or clinical trial independent data monitoring committee membership with various pharmaceutical companies, including Novartis.

Source: Masouridi-Levrat S et al. Bone Marrow Transplant. 2021 Oct 1. doi: 10.1038/s41409-021-01472-x.

Key clinical point: In real-life settings, patients with chronic myeloid leukemia (CML) in accelerated or chronic phase treated with new-generation tyrosine kinase inhibitor (NG-TKI) therapy in first line were more likely to achieve major molecular response (MMR) vs. those treated with imatinib.

Major finding: Patients receiving NG-TKI vs. imatinib were more likely to achieve MMR (77% vs. 61%; hazard ratio 1.88; 95% CI 1.35-2.61).

Study details: Findings are from a retrospective, population-based study including 507 adult patients with chronic or accelerated phase CML treated first with either imatinib (n = 388) or NG-TKI (nilotinib, n = 90; dasatinib, n = 24; bosutinib, n = 3; ponatinib, n = 2).

Disclosures: This study was funded by Force Hémato with the support of Novartis and supported by La Ligue Contre le Cancer. P Cony-Makhoul reported grants from Force Hémato. Other authors declared no conflict of interests.

Source: Canet J et al. Cancer Med 2021 Sep 22. doi: 10.1002/cam4.4186.

Key clinical point: In real-life settings, patients with chronic myeloid leukemia (CML) in accelerated or chronic phase treated with new-generation tyrosine kinase inhibitor (NG-TKI) therapy in first line were more likely to achieve major molecular response (MMR) vs. those treated with imatinib.

Major finding: Patients receiving NG-TKI vs. imatinib were more likely to achieve MMR (77% vs. 61%; hazard ratio 1.88; 95% CI 1.35-2.61).

Study details: Findings are from a retrospective, population-based study including 507 adult patients with chronic or accelerated phase CML treated first with either imatinib (n = 388) or NG-TKI (nilotinib, n = 90; dasatinib, n = 24; bosutinib, n = 3; ponatinib, n = 2).

Disclosures: This study was funded by Force Hémato with the support of Novartis and supported by La Ligue Contre le Cancer. P Cony-Makhoul reported grants from Force Hémato. Other authors declared no conflict of interests.

Source: Canet J et al. Cancer Med 2021 Sep 22. doi: 10.1002/cam4.4186.

Key clinical point: In real-life settings, patients with chronic myeloid leukemia (CML) in accelerated or chronic phase treated with new-generation tyrosine kinase inhibitor (NG-TKI) therapy in first line were more likely to achieve major molecular response (MMR) vs. those treated with imatinib.

Major finding: Patients receiving NG-TKI vs. imatinib were more likely to achieve MMR (77% vs. 61%; hazard ratio 1.88; 95% CI 1.35-2.61).

Study details: Findings are from a retrospective, population-based study including 507 adult patients with chronic or accelerated phase CML treated first with either imatinib (n = 388) or NG-TKI (nilotinib, n = 90; dasatinib, n = 24; bosutinib, n = 3; ponatinib, n = 2).

Disclosures: This study was funded by Force Hémato with the support of Novartis and supported by La Ligue Contre le Cancer. P Cony-Makhoul reported grants from Force Hémato. Other authors declared no conflict of interests.

Source: Canet J et al. Cancer Med 2021 Sep 22. doi: 10.1002/cam4.4186.

Key clinical point: Frontline nilotinib vs. imatinib therapy showed a positive benefit-risk ratio in Japanese patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CML-CP) at 10 years of follow-up.

Major finding: At 10 years, a higher proportion of patients achieved major molecular response (MR) and MR4.5 in the 300 mg (86.2% and 65.5%) and 400 mg (78.3% and 69.6%) nilotinib arms compared to the imatinib (60.0% and 48.0%) arm. Cardiovascular adverse events (14.3% and 18.2% vs. 0.0%) were more frequent with 300 and 400 mg nilotinib vs. imatinib.

Study details: Findings are from a 10-year follow-up of a Japanese subgroup of patients with newly diagnosed Ph+ CML-CP from the phase 3 ENESTnd trial randomly assigned to receive either 300 mg nilotinib twice daily (n = 29), 400 mg nilotinib twice daily (n = 23), or 400 mg imatinib once daily (n = 25).

Disclosures: No funding source was identified other than medical writing assistance funded by Novartis Pharma KK. Some investigators, including the lead author, reported being employees of or receiving research support and personal fees from various sources, including Novartis.

Source: Nakamae H et al. Int J Hematol. 2021 Sep 11. doi: 10.1007/s12185-021-03216-5.

Key clinical point: Frontline nilotinib vs. imatinib therapy showed a positive benefit-risk ratio in Japanese patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CML-CP) at 10 years of follow-up.

Major finding: At 10 years, a higher proportion of patients achieved major molecular response (MR) and MR4.5 in the 300 mg (86.2% and 65.5%) and 400 mg (78.3% and 69.6%) nilotinib arms compared to the imatinib (60.0% and 48.0%) arm. Cardiovascular adverse events (14.3% and 18.2% vs. 0.0%) were more frequent with 300 and 400 mg nilotinib vs. imatinib.

Study details: Findings are from a 10-year follow-up of a Japanese subgroup of patients with newly diagnosed Ph+ CML-CP from the phase 3 ENESTnd trial randomly assigned to receive either 300 mg nilotinib twice daily (n = 29), 400 mg nilotinib twice daily (n = 23), or 400 mg imatinib once daily (n = 25).

Disclosures: No funding source was identified other than medical writing assistance funded by Novartis Pharma KK. Some investigators, including the lead author, reported being employees of or receiving research support and personal fees from various sources, including Novartis.

Source: Nakamae H et al. Int J Hematol. 2021 Sep 11. doi: 10.1007/s12185-021-03216-5.

Key clinical point: Frontline nilotinib vs. imatinib therapy showed a positive benefit-risk ratio in Japanese patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukemia (CML-CP) at 10 years of follow-up.

Major finding: At 10 years, a higher proportion of patients achieved major molecular response (MR) and MR4.5 in the 300 mg (86.2% and 65.5%) and 400 mg (78.3% and 69.6%) nilotinib arms compared to the imatinib (60.0% and 48.0%) arm. Cardiovascular adverse events (14.3% and 18.2% vs. 0.0%) were more frequent with 300 and 400 mg nilotinib vs. imatinib.

Study details: Findings are from a 10-year follow-up of a Japanese subgroup of patients with newly diagnosed Ph+ CML-CP from the phase 3 ENESTnd trial randomly assigned to receive either 300 mg nilotinib twice daily (n = 29), 400 mg nilotinib twice daily (n = 23), or 400 mg imatinib once daily (n = 25).

Disclosures: No funding source was identified other than medical writing assistance funded by Novartis Pharma KK. Some investigators, including the lead author, reported being employees of or receiving research support and personal fees from various sources, including Novartis.

Source: Nakamae H et al. Int J Hematol. 2021 Sep 11. doi: 10.1007/s12185-021-03216-5.